Vetr Lowers AbbVie (ABBV) to Buy

Leslie Hanson
January 17, 2018

Woodford Investment Management Ltd now owns 11,854,758 shares of the company's stock valued at $859,589,000 after purchasing an additional 937,500 shares in the last quarter. Roundview Capital Llc acquired 6,400 shares as Abbvie Inc (ABBV)'s stock rose 6.17%. The company's quarterly revenue was up 8.8% compared to the same quarter last year. equities research analysts predict that AbbVie will post 5.54 earnings per share for the current year. Of those analysts, 9 rate stock as a Strong Buy, 7 rate it as Hold, and just no analyst rates it as a Moderate Sell. AbbVie Inc. (NYSE:ABBV) has a 20-Day average volume of 4.28 Million. With that said, researchers took a deep dive into the hotly debated question: is it too late to buy AbbVie Inc.

AbbVie (NYSE ABBV) traded up $2.15 during midday trading on Wednesday, hitting $102.49.

AbbVie Inc. has a consensus outperform rating from 22 Wall Street analysts, and the number of shares now sold short amount to at least 1.06% of shares outstanding. About 1.59 million shares traded. 87,040 AbbVie Inc. (NYSE:ABBV) shares with value of $8.57 million were sold by RICHMOND TIMOTHY J. Meanwhile, the past 2-3 months have been strong for the company as it presented promising data from several pivotal studies, gained regulatory approvals in the U.S., Europe, and Japan for its competitive HCV medicine Mavyret and FDA approval for the sixth indication for Imbrivica and settled its Humira patent disputes with Amgen. In the previous year there have been a total of 60 insider trades, including 21 open market buys and 39 sells. (NYSE:ABBV) shares were sold by Schumacher Laura J. Michael Robert A. sold $589,512 worth of stock. The stock increased 1.53% or $1.57 during the last trading session, reaching $104.06.

In other news, Chairman Richard A. Gonzalez sold 218,193 shares of the business's stock in a transaction dated Tuesday, November 21st. The rating was maintained by Jefferies on Monday, July 17 with "Buy".

Analysts await AbbVie Inc. The firm has a market cap of $163,380.00, a price-to-earnings ratio of 24.88, a P/E/G ratio of 1.20 and a beta of 1.53. For shareholders, given the total diluted outstanding shares of 1.6 billion, this means overall earnings per share of 1.01. 387.06 million shares or 0.01% more from 387.02 million shares in 2017Q2 were reported. 1832 Asset Mgmt Ltd Partnership invested in 0% or 12,768 shares. (ABBV) most recent 13F filing, the company has 124 new institutional holders - accounting for 10.26 million shares of its common stock. St. Louis Trust Co now owns 3,411 shares of the company's stock valued at $248,000 after purchasing an additional 23 shares during the period.

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The stock has "Buy" rating by Goldman Sachs on Friday, March 10. WealthTrust Axiom LLC now owns 4,307 shares of the company's stock worth $312,000 after acquiring an additional 15 shares during the period. The firm earned "Hold" rating on Wednesday, April 19 by BMO Capital Markets.

More notable recent AbbVie Inc.

11/21/2017 - AbbVie had its "hold" rating reaffirmed by analysts at BMO Capital Markets. (NYSE:ABBV) on Monday, November 2 to "Overweight" rating. The Washington-based Coldstream Management Inc has invested 0.42% in AbbVie Inc. Boston Ltd Liability holds 0.32% or 159,186 shares in its portfolio. (NYSE:ABBV) on Monday, August 7. Yatra Online, Inc. (NASDAQ:YTRA) has 0.00% since January 17, 2017 and is. (NYSE:ABBV). Wellington Shields Management Limited Company holds 0.58% in AbbVie Inc. (NYSE:ABBV). Hennessy Advisors holds 117,400 shares. Kayne Anderson Rudnick Management Llc has 3,300 shares for 0% of their portfolio. LUCAS ROGER C also sold $12,196 worth of Bio-Techne Corporation (NASDAQ:TECH) on Tuesday, October 10. (NYSE:ABBV). Rfg Advisory Group Incorporated Ltd reported 0.78% of its portfolio in AbbVie Inc. The stock was sold at an average price of $90.55, for a total value of $1,657,065.00. The company reported $1.41 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.39 by $0.02. Finally, Jefferies Group reissued a "buy" rating and set a $107.00 target price on shares of AbbVie in a research report on Thursday, September 28th.

Since January 1, 0001, it had 0 insider buys, and 8 sales for $3.79 million activity.

AbbVie (NYSE ABBV) traded up $2.15 during trading hours on Monday, reaching $102.49. First Personal Ser stated it has 0.33% in AbbVie Inc. (NYSE:ABBV) for 61,740 shares. (NYSE:ABBV) or 1.24M shares. Caz Investments LP holds 1.22% or 4,750 shares in its portfolio.

Vaughan David Investments Inc, which manages about $1.81B and $2.04 billion US Long portfolio, upped its stake in Verizon Communications (NYSE:VZ) by 7,362 shares to 651,816 shares, valued at $32.26M in 2017Q3, according to the filing. SALEKI-GERHARDT AZITA sold 8,300 shares worth $705,655. Cape Cod Five Cents Fincl Bank invested in 30,433 shares. Old Mutual Global Invsts (Uk) Limited reported 0.02% stake. Somerville Kurt F has 29,150 shares for 0.52% of their portfolio. Endurance Wealth Management reported 103,302 shares or 1.52% of all its holdings. AbbVie's revenue was up 7.4% on a year-over-year basis. Marble Harbor Invest Counsel Limited Com, Massachusetts-based fund reported 200,564 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Other reports by Iphone Fresh

Discuss This Article